ABOUT LPOXY THERAPEUTICS

LPOXY Therapeutics, Inc. is a privately held biopharmaceutical corporation at the forefront of developing innovative treatments for patients at risk of antibiotic-induced superinfections. Our flagship product, LP-102, is the first orally-administered metered-dose intestinal oxygen delivery therapeutic designed to prevent C. difficile colitis infections in at-risk patients undergoing antibiotic therapy. Founded in 2020 by renowned scientific luminary Dr. Porter W. Anderson, Jr. and seasoned physician-scientist Dr. Larry D. Sutton, LPOXY Therapeutics continues the founders’ legacy of pioneering anti-infective solutions. Their previous venture, Sopharmia Inc., was successfully acquired by venture-backed Gladius Pharmaceuticals, Inc. in 2015.

Since its inception, LPOXY Therapeutics has expanded the potential applications of LP-102 to include treating inflammatory bowel diseases, supported by a robust patent portfolio that safeguards our innovative technology. Currently poised to enter Phase 2 clinical trials, LP-102 represents a significant advancement in gastrointestinal healthcare, with development rigorously guided by preliminary regulatory discussions with the FDA.

As we aim to secure the necessary capital to advance our Phase 2 clinical trials, we are committed to pushing the boundaries of medical science to improve patient outcomes. LPOXY Therapeutics is actively seeking strategic partnerships and investment opportunities to support our next stages of growth.

We invite you to join us on this exciting journey. For more information on investment opportunities or to stay updated on our progress, please [Contact Us] or follow us on LinkedIn. Together, we can redefine the future of gastrointestinal treatment.